TY - JOUR T1 - Detection of SARS-CoV-2 in air and on surfaces in rooms of infected nursing home residents JF - medRxiv DO - 10.1101/2022.02.16.22271053 SP - 2022.02.16.22271053 AU - K.J. Linde AU - I.M. Wouters AU - J.A.J.W. Kluytmans AU - M.F.Q. Kluytmans-van den Bergh AU - S.D. Pas AU - C.H. GeurtsvanKessel AU - M.P.G. Koopmans AU - M. Meier AU - P. Meijer AU - C.R. Raben AU - J. Spithoven AU - M.H.G. Tersteeg-Zijderveld AU - D.J.J. Heederik AU - W. Dohmen AU - COCON consortium Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/02/25/2022.02.16.22271053.abstract N2 - There is an ongoing debate on airborne transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) as a risk factor for infection. In this study, the level of SARS-CoV-2 in air and on surfaces of SARS-CoV-2 infected nursing home residents was assessed to gain insight in potential transmission routes.During outbreaks, air samples were collected using three different active and one passive air sampling technique in rooms of infected patients. Oropharyngeal swabs (OPS) of the residents and dry surface swabs were collected. Additionally, longitudinal passive air samples were collected during a period of 4 months in common areas of the wards. Presence of SARS-CoV-2 RNA was determined using RT-qPCR, targeting the RdRp- and E-genes. OPS, samples of two active air samplers and surface swabs with Ct value ≤35 were tested for the presence of infectious virus by cell culture. In total, 360 air and 319 surface samples from patient rooms and common areas were collected. In rooms of 10 residents with detected SARS-CoV-2 RNA in OPS, SARS-CoV-2 RNA was detected in 93 of 184 collected environmental samples (50.5%) (lowest Ct 29,5), substantially more than in the rooms of residents with negative OPS on the day of environmental sampling (n=2) (3.6%). SARS-CoV-2 RNA was most frequently present in the larger particle size fractions (>4 μm 60% (6/10); 1-4 μm 50% (5/10); <1 μm 20% (2/10)) (Fischer exact test p=0.076). The highest proportion of RNA-positive air samples on room level was found with a filtration-based sampler 80% (8/10) and the cyclone-based sampler 70% (7/10), and impingement-based sampler 50% (5/10). SARS-CoV-2 RNA was detected in ten out of twelve (83%) passive air samples in patient rooms. Both high-touch and low-touch surfaces contained SARS-CoV-2 genome in rooms of residents with positive OPS (high 38% (21/55); low 50% (22/44)). In one active air sample, infectious virus in vitro was detected.In conclusion, SARS-CoV-2 is frequently detected in air and on surfaces in the immediate surroundings of room-isolated COVID-19 patients, providing evidence of environmental contamination. The environmental contamination of SARS-CoV-2 and infectious aerosols confirm the potential for transmission via air up to several meters.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is funded by ZonMw and part of Control of COVID-19 iN Hospitals (COCON) consortium.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No medical ethical approval was needed for this study as evaluated by the Medical Research Ethics Committee of University Medical Centre Utrecht; a declaration of non-compliance with the scope of the Dutch Medical Research Involving Human Subject Act was obtained.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -